Andere talen Avalo Therapeutics, Inc.

Aandelen

AVTX

US05338F3064

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 07-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
13,25 ^USD	-1,92%		-22,61%	+45,60%

16/04	AVALO THERAPEUTICS, INC. : Oppenheimer verhoogt advies van Neutraal naar Kopen	ZM
29/03	Avalo Therapeutics, Inc. rapporteert winstresultaten voor het volledige jaar dat eindigde op 31 december 2023	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

North American Morning Briefing : Stock Futures -2-	17/04
Avalo Therapeutics Appoints Biotech Leaders to Board of Directors	02/04
Avalo Reports 2023 Financial Results and Provides Business Updates	01/04
Avalo Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29/03
Avalo Reports 2023 Financial Results and Provides Business Updates	29/03
Sector Update: Health Care Stocks Rise Late Afternoon	28/03
Top Midday Gainers	28/03
Wall Street Set to Open Flat in Thursday Trading; Q4 US GDP Revised Up, Weekly Jobless Claims Fall	28/03
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Thursday Ahead of Key Economic Data	28/03
US Futures Little Changed Pre-Bell Thursday Ahead of Raft of Economic Data	28/03
Top Premarket Gainers	28/03
Avalo Therapeutics, Inc. announced that it has received $115.6 million in funding from Deep Track Capital, LP, TCG Crossover Management, LLC, BVF Partners L.P., RA Capital Management, L.P., Commodore Capital LP, Petrichor Holdings, LLC	28/03
Avalo Therapeutics, Inc. acquired AlmataBio, Inc. for $42.5 million.	28/03
Avalo Therapeutics Shares Triple After Acquisition of AlmataBio, Private Placement Financing of Up to $185 Million	27/03
Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million	27/03
Avalo Therapeutics, Inc. Announces Board Appointments	27/03
North American Morning Briefing : Stocks Edge -2-	27/03
Avalo Therapeutics, Inc. announced that it expects to receive $115.6 million in funding from Deep Track Capital, LP, TCG Crossover Management, LLC, Commodore Capital, BVF Partners L.P., Petrichor Energy Inc., RA Capital Management, L.P.	27/03
Avalo Therapeutics Plans 1-for-240 Reverse Stock Split	27/12
Avalo Therapeutics Announces 1-for-240 Reverse Stock Split	27/12

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Avalo Therapeutics, Inc.

Aandelen

AVTX

US05338F3064

Andere talen

Filters